Malaysia · Delayed Price · Currency is MYR Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 1.74 billion. The enterprise value is 2.35 billion.
| Market Cap | 1.74B |
| Enterprise Value | 2.35B |
Important Dates
The next estimated earnings date is Wednesday, August 19, 2026.
| Earnings Date | Aug 19, 2026 |
| Ex-Dividend Date | Jun 5, 2026 |
Share Statistics
KLSE:PHARMA has 1.31 billion shares outstanding. The number of shares has increased by 239.48% in one year.
| Current Share Class | 1.31B |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | +239.48% |
| Shares Change (QoQ) | +81.45% |
| Owned by Insiders (%) | 6.34% |
| Owned by Institutions (%) | 11.87% |
| Float | 367.23M |
Valuation Ratios
The trailing PE ratio is 25.85 and the forward PE ratio is 7.25.
| PE Ratio | 25.85 |
| Forward PE | 7.25 |
| PS Ratio | 0.43 |
| PB Ratio | 3.56 |
| P/TBV Ratio | 4.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.87, with an EV/FCF ratio of -25.95.
| EV / Earnings | 46.66 |
| EV / Sales | 0.58 |
| EV / EBITDA | 14.87 |
| EV / EBIT | 19.08 |
| EV / FCF | -25.95 |
Financial Position
The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.63.
| Current Ratio | 0.92 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.63 |
| Debt / EBITDA | 5.06 |
| Debt / FCF | -8.83 |
| Interest Coverage | 2.28 |
Financial Efficiency
Return on equity (ROE) is 28.41% and return on invested capital (ROIC) is 8.27%.
| Return on Equity (ROE) | 28.41% |
| Return on Assets (ROA) | 3.43% |
| Return on Invested Capital (ROIC) | 8.27% |
| Return on Capital Employed (ROCE) | 18.95% |
| Weighted Average Cost of Capital (WACC) | 7.29% |
| Revenue Per Employee | 1.16M |
| Profits Per Employee | 14,392 |
| Employee Count | 3,502 |
| Asset Turnover | 1.80 |
| Inventory Turnover | 5.83 |
Taxes
In the past 12 months, KLSE:PHARMA has paid 23.02 million in taxes.
| Income Tax | 23.02M |
| Effective Tax Rate | 30.43% |
Stock Price Statistics
The stock price has increased by +1.18% in the last 52 weeks. The beta is 0.77, so KLSE:PHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +1.18% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 52.28 |
| Average Volume (20 Days) | 4,681,236 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 4.05 billion and earned 50.40 million in profits. Earnings per share was 0.05.
| Revenue | 4.05B |
| Gross Profit | 410.10M |
| Operating Income | 123.24M |
| Pretax Income | 75.64M |
| Net Income | 50.40M |
| EBITDA | 147.62M |
| EBIT | 123.24M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 217.30 million in cash and 799.81 million in debt, with a net cash position of -582.50 million or -0.44 per share.
| Cash & Cash Equivalents | 217.30M |
| Total Debt | 799.81M |
| Net Cash | -582.50M |
| Net Cash Per Share | -0.44 |
| Equity (Book Value) | 489.50M |
| Book Value Per Share | 0.35 |
| Working Capital | -140.86M |
Cash Flow
In the last 12 months, operating cash flow was -60.67 million and capital expenditures -29.94 million, giving a free cash flow of -90.61 million.
| Operating Cash Flow | -60.67M |
| Capital Expenditures | -29.94M |
| Depreciation & Amortization | 24.38M |
| Net Borrowing | -334.17M |
| Free Cash Flow | -90.61M |
| FCF Per Share | -0.07 |
Margins
Gross margin is 10.12%, with operating and profit margins of 3.04% and 1.24%.
| Gross Margin | 10.12% |
| Operating Margin | 3.04% |
| Pretax Margin | 1.87% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.64% |
| EBIT Margin | 3.04% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 1.88%.
| Dividend Per Share | 0.03 |
| Dividend Yield | 1.88% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -239.48% |
| Shareholder Yield | -237.54% |
| Earnings Yield | 2.89% |
| FCF Yield | -5.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KLSE:PHARMA is 0.69, which is -48.12% lower than the current price. The consensus rating is "Buy".
| Price Target | 0.69 |
| Price Target Difference | -48.12% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 4.65% |
| EPS Growth Forecast (3Y) | 79.89% |
Stock Splits
The last stock split was on June 8, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KLSE:PHARMA has an Altman Z-Score of 2.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 3 |